Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinoma (NSCLC) with specific EGFR (epidermal growth factor receptor) mutations. It is a third-generation EGFR tyrosine kinase inhibitor (TKI) designed to target both sensitizing EGFR mutations and the T790M resistance mutation, which makes it effective even in patients who have developed resistance to earlier-generation TKIs.Osimertinib is taken orally once daily and has shown improved progression-free survival in NSCLC patients.
Parent: Osimertinib
Parent: Osimertinib
Parent: Osimertinib
Parent: Osimertinib
Parent: Osimertinib
Parent: Osimertinib
Parent: Osimertinib
Parent: Osimertinib
Parent: Osimertinib
Parent: Osimertinib
Parent: Osimertinib
Parent: Osimertinib/ Osimertinib Mesylate
Parent: Osimertinib
Impurities in Osimertinib can arise due to synthesis processes, degradation, or storage conditions. Regulatory authorities like the FDA, ICH, and EMA enforce strict impurity limits to ensure the drug’s safety and efficacy.
Process-Related Impurities
• Unreacted intermediates from chemical synthesis
• Residual solvents (e.g., methanol, ethanol, dichloromethane)
• By-products from synthetic reactions
Degradation Impurities
• Oxidation by-products due to exposure to oxygen or light
• Hydrolysis impurities from moisture exposure
• Thermal degradation products under high temperatures
Elemental Impurities
• Heavy metals from catalysts used in synthesis
• Trace levels of lead, arsenic, cadmium, mercury**
Analytical Techniques for Impurity Detection
• High-Performance Liquid Chromatography (HPLC)
• Gas Chromatography (GC)
• Mass Spectrometry (MS)
• Fourier-Transform Infrared Spectroscopy (FT-IR)
Patients taking Tagrisso (Osimertinib) should avoid grapefruit and grapefruit juice, as they may interfere with drug metabolism. Also, avoid strong CYP3A4 inducers such as rifampin, phenytoin, or St. John’s Wort, which can reduce the effectiveness of the medication.
Patients should undergo regular monitoring of lung function, heart function (QT prolongation), and liver function. Caution is advised in patients with pre-existing heart disease, liver impairment, or lung disease (interstitial lung disease, ILD).
Osimertinib is usually taken once daily, and there is no strict timing requirement, but it should be taken at the same time every day for consistency. It can be taken with or without food.
Moderate alcohol consumption may not directly interfere with osimertinib, but it is advisable to limit alcohol intake, especially if the patient has liver issues, fatigue, or nausea, which are common side effects of the medication.
